News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
775,836 Results
Type
Article (75782)
Company Profile (488)
Press Release (699566)
Section
Business (219061)
Career Advice (3079)
Deals (37710)
Drug Delivery (107)
Drug Development (88788)
Employer Resources (177)
FDA (17473)
Job Trends (16572)
News (374851)
Policy (37285)
Tag
Academia (2963)
Africa (1098)
Alliances (55106)
Alzheimer's disease (1263)
Approvals (17391)
Arizona (183)
Artificial intelligence (100)
Asia (46373)
Australia (8023)
Bankruptcy (364)
Best Places to Work (12248)
Biotechnology (330)
Breast cancer (79)
C2C Services and Suppliers (85248)
California (2210)
Canada (1014)
Cancer (661)
Career advice (2604)
Cell therapy (171)
China (173)
Clinical research (69393)
Collaboration (209)
Colorado (95)
Compensation (104)
Connecticut (99)
COVID-19 (2763)
Cystic fibrosis (83)
Data (479)
Diabetes (108)
Diagnostics (6489)
Drug pricing (94)
Earnings (85404)
Employer resources (156)
Europe (105152)
Events (119408)
Executive appointments (195)
FDA (17782)
Florida (313)
Funding (192)
Gene therapy (117)
GLP-1 (631)
Government (4935)
Healthcare (20545)
Hotbed/Location (508979)
Illinois (323)
Indiana (167)
Infectious disease (2805)
Inflammatory bowel disease (105)
Interviews (564)
IPO (17026)
Job creations (4564)
Job search strategy (2189)
Kansas (99)
Layoffs (467)
Legal (9314)
Lung cancer (136)
Manufacturing (125)
Maryland (465)
Massachusetts (1872)
Medical device (14159)
Medtech (14164)
Mergers & acquisitions (20587)
Metabolic disorders (339)
Michigan (146)
Minnesota (243)
Neuroscience (1469)
New Jersey (682)
New York (684)
NextGen Class of 2024 (7419)
Non-profit (5018)
North Carolina (715)
Northern California (942)
Obesity (203)
Ohio (119)
Opinion (234)
Patents (87)
Pennsylvania (643)
People (61180)
Pharmaceutical (112)
Phase I (21308)
Phase II (30233)
Phase III (22837)
Pipeline (140)
Podcasts (77)
Postmarket research (3332)
Preclinical (9442)
Radiopharmaceuticals (252)
Rare diseases (166)
Real estate (6875)
Regulatory (24171)
Research institute (2625)
Resumes & cover letters (476)
South America (1486)
Southern California (866)
Startups (4056)
Texas (299)
United States (10080)
Vaccines (587)
Washington State (286)
Weight loss (182)
Date
Today (146)
Last 7 days (733)
Last 30 days (2987)
Last 365 days (39311)
2024 (29213)
2023 (42439)
2022 (53826)
2021 (58599)
2020 (57485)
2019 (50987)
2018 (38821)
2017 (36182)
2016 (36725)
2015 (42837)
2014 (36911)
2013 (33297)
2012 (34834)
2011 (34800)
2010 (34335)
775,836 Results for "johnson and johnson pharmaceutical research and development llc pa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Johnson & Johnson Completes Acquisition of Shockwave Medical
Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
May 31, 2024
·
5 min read
Press Releases
Johnson & Johnson Celebrates Innovation in Regulated RNA and Protein Degradation with 2024 Dr. Paul Janssen Award for Biomedical Research
September 26, 2024
·
5 min read
Pharm Country
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization
Johnson & Johnson announced a proposed Plan of Reorganization by its subsidiary, LLT Management LLC, for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates in the United States.
May 1, 2024
·
8 min read
Deals
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD).
May 16, 2024
·
8 min read
Proteologix, Inc. to be Acquired by Johnson & Johnson
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson
May 16, 2024
·
2 min read
Pharm Country
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024
Johnson & Johnson today announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024.
May 3, 2024
·
8 min read
Business
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics to acquire from Numab’s shareholders its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26, in an all-cash transaction of approximately $1.25 billion.
May 28, 2024
·
6 min read
Pharm Country
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease
Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn’s disease.
June 20, 2024
·
21 min read
Pharm Country
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12th, at the Loews Miami Beach Hotel, Miami Beach, Florida.
May 8, 2024
·
1 min read
Pharm Country
Johnson & Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes
Johnson & Johnson announced positive topline results from the pivotal Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of seltorexant as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms.
May 29, 2024
·
19 min read
1 of 77,584
Next
